ClinicalTrials.gg
RecruitingNCT04748796HyperBetashockUpdated Aug 24, 2025

Comparison of Landiolol Versus Standard of Care for Prevention of Mortality in Patients Hospitalized for a Septic Shock With Hypercontractility

A Phase 3 interventional study of echocardiography and Landiolol in Septic Shock, Tachycardia and Mortality During Septic Shock, sponsored by Centre Hospitalier Universitaire, Amiens. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-24.

Sponsored by Centre Hospitalier Universitaire, Amiens · Phase 3, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Feb 2021; still recruiting 5 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Shock, Septic by Centre Hospitalier Universitaire, Amiens — 6 open to participants now, 7 under way, 2 of them phase 3. Shock, Septic · Centre Hospitalier Universitaire, Amiens.

Started
2021
with 1 other
Phase 3
2 of 11
1 open now
Registered
6th of 11
by date

Among the 11 studies in Shock, Septic by Centre Hospitalier Universitaire, Amiens, this one is one of 2 that started in 2021, is one of 2 in phase 3, and was the 6th registered.

Shock, Septic

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

6 of the 11 studies in Shock, Septic by Centre Hospitalier Universitaire, Amiens are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Shock, Septic by Centre Hospitalier Universitaire, Amiens, or all of them as a file.
02

Study summary

Several data emphasize the relation between tachycardia (>90/min) and high mortality during septic shock. The investigators previously demonstrated the high mortality associated with hypercontractility, tachycardia and the presence of a left ventricular obstruction. A severe hypovolemia, a hyper adrenergic stimulation or a severe vasoplegia can all explain this relation between tachycardia, hypercontractility and the mortality during septic shock.

Landiolol is another short-term acting beta-blocker with a half-life of 4 minutes without any beta 2 activity or membrane stabilizing effect. The landiolol has been used in critically ill patients to control supraventricular tachycardia but not in this context of tachycardia and septic shock. The investigators hypothesize that landiolol by reducing the heart rate may improve the survival of patients treated for a septic shock and presenting with an hypercontractility state.

03

Conditions studied

  • Septic Shock
  • Tachycardia
  • Mortality During Septic Shock
  • Beta-blocker

Keywords

  • Septic Shock
  • Tachycardia
  • mortality during septic shock
  • beta-blocker
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years old
  • Patient admitted for a septic shock (according to the SEPSIS3 definition: sepsis with persisting hypotension (MAP\<65mmHg or SAP \<90mmHg) requiring vasopressors to maintain MAP>65mmHg and having a serum lactate level >2 mmol/L
  • Patient who received at least 30ml/kg of fluid and absence of fluid responsiveness
  • >65% (visual or Simpson method using echocardiography)
  • Tachycardia >100 bpm in sinus rhythm with a MAP 65mmHg for more than 1 hour
  • Patient receiving invasive mechanical ventilation
  • Patients adapted to the ventilator under sedation and analgesia
  • Written
  • Patient covered by French national health insurance

Exclusion criteria

Exclusion Criteria:

  • Patients with inclusion criteria already present for more than 36 hours
  • Patient treated with Dobutamine, adrenaline or isoprenaline
  • Patient currently treated with beta blockers (previous home betablocker treatment is not an exclusion criteria)
  • Supra ventricular (atrial fibrillation or flutter) or ventricular arrhythmias
  • Patients with any form of cardiac pacing
  • Sick sinus syndrome
  • Severe atrioventricular (AV) nodal conductance disorders (without pacemaker): 2nd or 3rd degree AV block
  • Known pulmonary hypertension
  • ScVO2 \<70%
  • Moribund
  • Cardiac arrest
  • Non-treated phaeochromocytoma
  • Acute asthmatic attack
  • Pregnant or breastfeeding woman
  • Patient deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision),
  • Age \<18 years
  • to the active substance or to any of the
  • Severe bradycardia (less than 50 beats per minute)
  • Cardiogenic shock
  • Severe hypotension
  • Decompensated heart failure when considered not related to the arrhythmia
  • Severe, uncorrectable metabolic acidosis
  • Presence of significant bleeding, or
  • Acute respiratory distress defined by increased oxygen dependency, polypnea > 30 /min, signs of struggle (pulling, thoraco-abdominal sway) if the patient is not intubated and ventilated.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    Experimental group

    2 days with landiolol IV + usual care

    Drug: Landiolol

  • Active comparator
    Control group

    usual care according to the attending physician and following the guidelines of surviving sepsis campaign.

    Other: echocardiography

Interventions

  • Otherechocardiography

    Full echocardiography will be performed at baseline and during the follow-up at H1, H3, H6 and H12.

  • Patients randomized to the experimental group will be treated according to the standard of care plus for 2 days with landiolol IV started at a dose of 1 microgram/kg/min and progressively increased every 10 minutes to a maximum of 40 micrograms/kg/min.

06

What researchers measure

Primary outcomes

  1. Variation of mortality rate in landiolol group compared to control group

    Time frame: day 28

07

Study locations

1 of 1 sites recruiting
  • CHU Amiens
    Amiens, 80480, France
    Recruiting
    • Michel Slama, Pr · Contactslama.michel@chu-amiens.fr · (33)3 22 08 78 41
    • Julien Maizel, Pr · Contactmaizel.julien@chu-amiens.fr · (33)3 22 08 78 07
    • Julien Maizel, Pr · Sub investigator
    • Herve Dupont, Pr · Sub investigator
    • Pierre Louis DECLERCQ, MD · Sub investigator
    • MICHOT, MD · Sub investigator
    • Mehdi BOUSTA, MD · Sub investigator
    • David LUIS, MD · Sub investigator
    • Geneviève BARJON, MD · Sub investigator
    • Eloi GOULLIEUX, MD · Sub investigator
    • Damien DU CHEYRON, MD · Sub investigator
    • Bertrand SAUNEUF, MD · Sub investigator
    • Saad NSEIR, MD · Sub investigator
    • Philippe MOREL, MD · Sub investigator
    • Jérôme LEPRETRE, MD · Sub investigator
    • Patrick HERBECQ, MD · Sub investigator
    • Christophe VINSONNEAU, MD · Sub investigator
    • Thierry VANDERLINDEN, MD · Sub investigator
    • Didier THEVENIN, MD · Sub investigator
    • Olivier LEROY, MD · Sub investigator
    • Fabien LAMBIOTTE, MD · Sub investigator
    • Maxime GRANIER, MD · Sub investigator
    • Antoine VIEILLARD BARON, MD · Sub investigator
    • Gwenael PRAT, MD · Sub investigator
    • Armand MEKONTSO DESSAP, MD · Sub investigator
    • Stephane GAUDRY, MD · Sub investigator
    • Kada KLOUCHE, MD · Sub investigator
    • Joseph BAYEKULA MAFULA, MD · Sub investigator
    • Bernard ALLAOUCHICHE, MD · Sub investigator
    • Laurent MULLER, MD · Sub investigator
    • Jean-Michel CONSTANTIN, MD · Sub investigator
    • UHEL, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2021 (actual). Primary completion is estimated for Jun 2027, 76 months after the start.

Of 45 non-industry phase 3 interventional studies under Shock, Septic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 59. This study's planned 76 months is above that.

Counting every sponsor, half of 46 studies reached it within 42 months; a quarter within 16 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2021
First posted
Feb 10, 2021
StartActual
Feb 1, 2021
Primary completionEst.
Jun 2027
CompletionEst.
Sep 2027
Last update
Aug 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04748796
Collaborators
CH Dieppe, CH Elbeuf, CH Le Havre, Centre Hospitalier de Beauvais, Centre Hospitalier Intercommunal de Compiègne-Noyon, CH Laon, University Hospital, Caen, CH Cherbourg, University Hospital, Lille, CH Douai, CH Montreuil, Centre Hospitalier de Roubaix, Centre Hospitalier de Bethune, CH Lomme, Centre Hospitalier de Lens, Tourcoing Hospital, Centre Hospitalier VALENCIENNES, Centre Hospitalier Arras, Hospital Ambroise Paré Paris, University Hospital, Brest, Henri Mondor University Hospital, Hospital Avicenne, University Hospital, Montpellier, CH Calais, Hôpital Edouard Herriot, Centre Hospitalier Universitaire de Nīmes, Groupe Hospitalier Pitie-Salpetriere, Hôpital Louis Mourier, Colombes
Responsible party
Sponsor
First posted
Feb 10, 2021
Start date
Feb 1, 2021
Primary completion
Jun 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Aug 24, 2025

Study contacts

Slama Michel, Pr
Contact
slama.michel@chu-amiens.fr
03 22 08 78 41

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Landiolol

Start the discussion